We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Women Choosing Surgical Prevention (WISP) Trial

This study is currently recruiting participants.
Verified November 2017 by M.D. Anderson Cancer Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT02760849
First Posted: May 4, 2016
Last Update Posted: November 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
American Association for Cancer Research
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
  Purpose

The goal of this clinical research study is to compare the changes in female sexual function between patients having interval salpingectomy with delayed oophorectomy (ISDO) with those having risk-reducing salpingo-oophorectomy (RRSO) in women who carry genetic mutations. Researchers also want to learn how these surgeries affect your quality of life.

RRSO is the standard surgery for patients with certain types of genetic mutations, where the fallopian tubes and ovaries are removed at the same time.

ISDO is surgery to remove the fallopian tubes first, then the ovaries are removed during a second, later surgery. Most women with genetic mutations will be encouraged to remove the ovaries around the ages of 40 to 50. The decision in timing to remove your ovaries will be made with your doctor.


Condition Intervention Phase
Hereditary Breast and Ovarian Cancer Syndrome Procedure: Salpingectomy Procedure: Oophorectomy Behavioral: Questionnaires Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: WISP (Women Choosing Surgical Prevention)

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Change in Sexual Function in Interval Salpingectomy with Delayed Oophorectomy (ISDO) Participants [ Time Frame: Baseline to 6 months after interval salpingectomy ]
    Change in sexual function measured by Female Sexual Function Index (FSFI). A change of 4 points is considered to be clinically meaningful.

  • Change in Sexual Function in Risk-Reducing Salpingo-Oophorectomy (RRSO) Participants [ Time Frame: Baseline to 6 months after bilateral salpingo-oophorectomy ]
    Change in sexual function measured by Female Sexual Function Index (FSFI). A change of 4 points is considered to be clinically meaningful.


Estimated Enrollment: 300
Actual Study Start Date: May 2016
Estimated Study Completion Date: May 2041
Estimated Primary Completion Date: May 2041 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Interval Salpingectomy with Delayed Oophorectomy (ISDO)

Participants who choose Group 1 will have ISDO. During salpingectomy, the inside of the abdomen is looked at and both fallopian tubes removed.

Quality-of-life questionnaires completed at baseline, 6 months after salpingectomy, and every year or until delayed oophorectomy.

During oophorectomy, the inside of the abdomen is looked at and both ovaries removed.

Quality-of-life questionnaires completed before oophorectomy, and at 6 months, 1 year, and 2 years after oophorectomy.

Procedure: Salpingectomy
During salpingectomy, the inside of the abdomen is looked at and both fallopian tubes removed.
Procedure: Oophorectomy
During oophorectomy, the inside of the abdomen is looked at and both ovaries removed.
Behavioral: Questionnaires

ISDO Group: Quality-of-life questionnaires completed at baseline, 6 months after salpingectomy, and every year or until delayed oophorectomy.

Quality-of-life questionnaires completed before oophorectomy, and at 6 months, 1 year, and 2 years after oophorectomy.

RRSO Group: Quality-of-life questionnaire completed at baseline, 6 months, 1 year, and 2 years after salpingo-oophorectomy surgery.

Other Name: Surveys
Experimental: Risk-Reducing Salpingo-Oophorectomy (RRSO)

Participants who choose Group 2 will have RRSO. During salpingo-oophorectomy, the inside of the abdomen looked at and both ovaries and fallopian tubes removed.

Quality-of-life questionnaire completed at 6 months, 1 year, and 2 years after salpingo-oophorectomy surgery.

Procedure: Salpingectomy
During salpingectomy, the inside of the abdomen is looked at and both fallopian tubes removed.
Procedure: Oophorectomy
During oophorectomy, the inside of the abdomen is looked at and both ovaries removed.
Behavioral: Questionnaires

ISDO Group: Quality-of-life questionnaires completed at baseline, 6 months after salpingectomy, and every year or until delayed oophorectomy.

Quality-of-life questionnaires completed before oophorectomy, and at 6 months, 1 year, and 2 years after oophorectomy.

RRSO Group: Quality-of-life questionnaire completed at baseline, 6 months, 1 year, and 2 years after salpingo-oophorectomy surgery.

Other Name: Surveys

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women must be >/= 30 and </= 50 years of age.
  2. Premenopausal women with a documented deleterious mutation in one of the following ovarian cancer genes: BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, PMS2, or EPCAM. (Please note: Menopause is defined as >/= 12 months of amenorrhea. However, for those patients with >/= 12 months of amenorrhea who may be pre-menopausal, levels of FSH, LH, and estradiol in the pre-menopausal range will be acceptable).
  3. Willing to undergo two surgical procedures (if participant chooses the ISDO arm)
  4. Presence of at least 1 fallopian tube and 1 ovary. (Please note: Prior unilateral salpingectomy is allowed; prior bilateral salpingectomy is not allowed)
  5. Patients who have undergone a prior tubal ligation will be eligible.
  6. Participants may have a personal history of non-ovarian malignancy, but must: a) be without evidence of disease at enrollment b) remain premenopausal c) have completed treatment (including surgery, chemotherapy, radiotherapy or hormonal therapy) >3 months prior to enrollment (other than non-melanoma skin cancer)
  7. Willingness to return to the enrolling site for the study surgical procedures, including pre-operative and post-operative care. (Patients in the ISDO arm must be willing to return to the enrolling site for yearly ovarian cancer assessment)
  8. Patients must understand that they will be permanently sterilized

Exclusion Criteria:

  1. Women with a personal history of ovarian, fallopian tube, or primary peritoneal cancer
  2. Current treatment with Tamoxifen or Aromatase Inhibitors
  3. Medical comorbidities making surgery unsafe as determined by the patient's surgeon
  4. Women who are pregnant or post-partum (within 3 months of delivery). -Patients are deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound, beta HCG, or best judgement of the investigator. Pregnancy testing is not required per protocol to determine study eligibility -Women who become pregnant on the ISDO arm via reproductive technology can remain on study. However, data collection will be suspended during pregnancy and 3 months post-partum
  5. Women with elevated levels of CA125 (>50) or transvaginal ultrasound suggesting cancer, unless findings are consistent with endometriosis. CA125 and transvaginal ultrasounds must be the most recent, but no older than 1 year from the date of enrollment.
  6. Inability to provide informed consent.
  7. Inability to read or speak English.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02760849


Contacts
Contact: Karen H. Lu, MD 832-750-1796

Locations
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States, 317556
Sponsors and Collaborators
M.D. Anderson Cancer Center
American Association for Cancer Research
Dana-Farber Cancer Institute
Investigators
Principal Investigator: Karen H. Lu, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT02760849     History of Changes
Other Study ID Numbers: 2015-0814
SU2C-AACR-DT16-15 ( Other Grant/Funding Number: American Association for Cancer Research Foundation )
NCI-2016-00778 ( Registry Identifier: NCI-CTRP )
First Submitted: May 2, 2016
First Posted: May 4, 2016
Last Update Posted: November 14, 2017
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by M.D. Anderson Cancer Center:
Hereditary Breast and Ovarian Cancer Syndrome
HBOC
Deleterious mutation in ovarian cancer genes
Changes in female sexual function
Salpingectomy with delayed oophorectomy
ISDO
Risk-reducing salpingo-oophorectomy (RRSO)
RRSO
Questionnaires
Surveys

Additional relevant MeSH terms:
Ovarian Neoplasms
Hereditary Breast and Ovarian Cancer Syndrome
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Breast Neoplasms
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn
Breast Diseases
Skin Diseases